Corbus Pharmaceuticals still shows promise, with CRB-701 and CRB-601 advancing in clinical trials. Read why CRBP stock is ...

Presented New CRB-913 Pre-Clinical Data at Obesity Week 2024 - Phase 1 Trial Expected to Commence in Q1 2025 ...

Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on CRBP stock, giving a Buy rating yesterday. Graig ...

Novo Nordisk's experimental obesity drug CagriSema shows similar side effects to its GLP-1 drugs, with potential for 25% ...

Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 ...

Bagsværd, 6 November 2024 - Financial report for the period 1 January 2024 to 30 September 2024 Operating profit increased by ...

Monlunabant was evaluated in a phase 2a trial (ClinicalTrials.gov Identifier: NCT05891834) in patients with obesity and metabolic syndrome (N=243). Results showed patients treated with monlunabant ...

Viking Therapeutics' weight loss drug VK2735 may challenge Novo Nordisk and Eli Lilly's dominance in the obesity drug space ...

CRB-913 brain levels are 15-fold lower than monlunabant in lean miceDose-response demonstrated for a range of 5 to 80 mg/kg/day achieving up to ...

However, shares in Novo Nordisk fell by nearly five per cent last month, after the company reported disappointing results from a phase 2a trial of its experimental obesity pill, monlunabant.

Based on these results a phase 2b trial is expected to begin in 2025. The larger trial will further assess monlunabant in obese patients over a longer duration. Results from a phase 2 trial ...

Novo is developing its own oral weight-loss drugs. Recent data has shown that Monlunabant, Novo’s once-a-day pill, has achieved statistically significant weight loss, however, it also showed ...